References
-
1
Barrett NR.
The lower oesophagus lined by columnar epithelium.
Surgery.
1957;
41
881-894
-
2
Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA.
Prevalence of columnar-lined Barrett's esophagus: comparison of population based clinical and autopsy findings.
Gastroenterology.
1990;
99
918-922
-
3
Chalsani N, Woo JM, Hunter JG, Waring SP.
Significance of intestinal metaplasia in different areas of the oesophagus including oesophagogastric junction.
Dig Dis Sci.
1997;
42
603-607
-
4
Hirota WK, Loughney TM, Lazas DJ, et al.
Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.
Gastroenterology.
1999;
116
277-285
-
5
Iascone C, DeMeester TR, Little AG, Skinner DB.
Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy.
Arch Surg.
1983;
118
543-549
-
6
Kahrilas PJ.
Anatomy and physiology of the gastroesophageal junction.
Gastroenterol Clin North Am.
1997;
3
467-485
-
7
Levine DS.
Management of dysplasia in the columnar-lined esophagus.
Gastroenterol Clin North Am.
1997;
3
613-634
-
8
Ormsby AH, Goldblum JR, Richter JE, et al.
Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
Hum Pathol.
1999;
30
288-294
-
9
Spechler SJ.
The columnar-lined esophagus: histology, terminology and clinical issues.
Gastroenterol Clin North Am.
1997;
26
445-466
-
10
Spechler SJ.
The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction.
Gastroenterology.
1999;
117
218-228
-
11
Spechler SJ, Goyal RK.
Barrett's esophagus.
N Engl J Med.
1986;
315
362-371
-
12
Van der Burgh A, Dees J, Hopp WCJ, van Blankenstein M.
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
Gut.
1996;
39
5-8
-
13
Wijnhoven BP, Siersema PD, Hop WC, et al.
Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity (Rotterdam Oesophageal Tumour Group).
Br J Surg.
1999;
86
529-535
-
14
Wright TA.
High-grade dysplasia in Barrett's oesophagus.
Br J Surg.
1997;
84
760-766
-
15
Bytzer P, Christensen PB, Damkier P, et al.
Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Am J Gastroenterol.
1999;
94
86-91
-
16
Devesa SS, Blot WJ, Fraumeni JF.
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.
Cancer.
1998;
83
2049-2053
-
17
Dolan K, Sutton R, Walker SJ, et al.
New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology.
Br J Cancer.
1999;
80
834-842
-
18
Hansen S, Wiig JN, Giercksky KE, Tretli S.
Esophageal and gastric carcinoma in Norway, 1958 - 1992: incidence, time trend variability according to morphological subtypes and organ subsites.
Int J Cancer.
1997;
71
340-344
-
19 National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER*Stat for Windows 95/NT, Version 1.1: SEER cancer incidence public-use database, 1993 - 1995. Bethesda, MD; US Department of Health and Human Services, 1997
-
20
Champion G, Richter JE, Vaezi MF, et al.
Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus.
Gastroenterology.
1994;
107
747-754
-
21
Collen MJ, Lewis JH, Benjamin SB.
Gastric acid hypersecretion in refractory gastroesophageal reflux disease.
Gastroenterology.
1990;
98
654-661
-
22
Eisen GM, Sandler RS, Murray S, Gottfried M.
The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus.
Am J Gastroenterol.
1997;
92
27-31
-
23
El-Serag HB, Sonnenberg A.
Opposing time trends of peptic ulcer and reflux disease.
Gut.
1998;
43
333
-
24
El-Serag HB, Sonnenberg A.
Associations among different forms of gastroesophageal reflux disease.
Gut.
1997;
41
594-599
-
25
Galmiche JP, Janssens J.
The pathophysiology of gastro-oesophageal reflux disease: an overview.
Scand J Gastroenterol.
1995;
30 (Suppl 211)
7-18
-
26
Lagergren J, Bergstrom R, Lindgren A, Nyren O.
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.
N Engl J Med.
1999;
340
825-831
-
27
Nebel OT, Fornes MF, Castell DO.
Symptomatic gastroesophageal reflux: incidence and precipitating factors.
Am J Dig Dis.
1976;
21
953-956
-
28 Sonnenberg A, El-Serag HB. Epidemiology of gastroesophageal reflux disease. In: Büchler MW, Farthmann EH Progress in Surgery, vol. 23. Basle; Karger 1997: 36
-
29
Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology.
1992;
102
1259-1268
-
30
Burtin P, Napoleon B, Palazzo L, et al.
Interobserver agreement in endoscopic ultrasonography staging of esophageal and cardia cancer.
Gastrointest Endosc.
1996;
43
20-24
-
31
Canto M.
Vital staining and Barrett's esophagus.
Gastrointest Endosc.
1999;
49
6
-
32
Eloubeidi MA, Provenzale D.
Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.
Am J Gastroenterol.
1999;
94
937-943
-
33
Ellis KK, Oehlke M, Helfand M, Lieberman D.
Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management?.
Am J Gastroenterol.
1997;
92
1472-1474
-
34
Ellis FH, Loda M.
Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett' s adenocarcinoma.
Dis Esophagus.
1997;
10
165-171
-
35
Murata Y.
The role of endoscopic ultrasonography for gastric cancer in the cardiac area [in Japanese].
Nippon Geka Gakkai Zasshi.
1998;
99
564-568
-
36
Tytgat GN.
Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any value?.
Endoscopy.
1995;
27
19-26
-
37
Tytgat GN.
Endoscopic features of the columnar-lined esophagus.
Gastroenterol Clin North Am.
1997;
3
507-517
-
38
Fennerty MB.
Perspectives on endoscopic eradication of Barrett's esophagus: who are appropriate candidates and what is the best method?.
Gastrointest Endosc.
1999;
49 (3)
24-28
-
39
Gossner L, Stolte M, Sroka R, et al.
Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid.
Gastroenterology.
1998;
114
448-455
-
40
Lightdale CJ.
Ablation therapy for Barrett's esophagus: is it time to choose our weapons?.
Gastrointest Endosc.
1999;
49
122-125
-
41
Overholt BF, Panjehpour M, Haydek JM.
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.
Gastrointest Endosc.
1999;
49
1-7
-
42
Van den Boogert J, van Hillegersberg R, Siersema PD, et al.
Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review.
Am J Gastroenterol.
1999;
94
1153-1160
-
43
Van Laethem JL, Cremer M, Peny MO, et al.
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results.
Gut.
1998;
43
747-751
-
44
Provenzale D, Kemp JA, Arora S, Wong JB.
A guide for surveillance of patients with Barrett's esophagus.
Am J Gastroenterol.
1994;
89
670-680
-
45 Sonnenberg A. Esophageal diseases. In: Everhart JE Digestive diseases in the United States: epidemiology and impact (US Department of Health and Human Services, NIH publication no. 94-1447). Washington, DC; US Government Printing Office 1994: 356
-
46
Sonnenberg A, El-Serag HB.
Economic aspects of endoscopic screening for intestinal precancerous conditions.
Gastrointest Endosc Clin North Am.
1997;
7
165-184
-
47
Sonnenberg A, Delco F, El-Serag HB.
Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.
Dig Dis Sci.
1998;
43
1001-1008
-
48
Wright TA, Gray MR, Morris AI, et al.
Cost-effectiveness of detecting Barrett's cancer.
Gut.
1996;
39
574-579
M.D. R. Lambert
International Agency for Research on Cancer
150, Cours A. Thomas
Lyon 69003
France
Telefon: +33-4-72110147
eMail: lambert@iarc. fr
